NCT00063778 - Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions

HIV Infections

Interventions

BIOLOGICAL

AVX101

Alphavirus replicon particle vaccine expressing HIV Gag antigen

OTHER

placebo

phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose

Trial Locations (7)

Columbia University, New York

New York Blood Ctr- Union Square, The Bronx

Vanderbilt University, Nashville

Johns Hopkins University, Baltimore

University of Rochester Medical Center, Rochester

SAAVI Vaccine Research Unit, Durban

Chris Hani Baragwanath Hospital, Soweto